Halozyme Therapeutics HALO Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's pre-tax income?
- Halozyme Therapeutics (HALO) reported pre-tax income of $180.33M in Q1 2026.
- How has Halozyme Therapeutics's pre-tax income changed year-over-year?
- Halozyme Therapeutics's pre-tax income increased by 25.4% year-over-year, from $143.83M to $180.33M.
- What is the long-term trend for Halozyme Therapeutics's pre-tax income?
- Over 3 years (2021 to 2024), Halozyme Therapeutics's pre-tax income has grown at a 30.9% compound annual growth rate (CAGR), from $248.52M to $557.13M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.